Veracyte Beheer
Beheer criteriumcontroles 4/4
De CEO Veracyte is Marc Stapley, benoemd in Jun2021, heeft een ambtstermijn van 5.25 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 7.42M, bestaande uit 9.4% salaris en 90.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.2% van de aandelen van het bedrijf, ter waarde $ 6.66M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4 jaar en 4.7 jaar.
Belangrijke informatie
Marc Stapley
Algemeen directeur
US$7.4m
Totale compensatie
| Percentage CEO-salaris | 9.43% |
| Dienstverband CEO | 5.3yrs |
| Eigendom CEO | 0.2% |
| Management gemiddelde ambtstermijn | 4yrs |
| Gemiddelde ambtstermijn bestuur | 4.7yrs |
Recente managementupdates
Recent updates
Seeking Alpha • Aug 10
Veracyte: Core Growth Funds Prosigna And TrueMRD
Summary Veracyte (VCYT) is evolving into a self-funded cancer diagnostic platform, leveraging clinical evidence, specialist relationships, and reimbursement infrastructure. Q2 2026 results showed 15% revenue growth, 23% adjusted EBITDA growth, and 29.2% EBITDA margin, with robust cash generation and no funded debt. Prosigna and TrueMRD launches offer significant upside, as 2026 guidance excludes their contributions, while Decipher and Afirma drive core growth and margin expansion. Valuation premium is justified by operational leverage, self-funded pipeline expansion, and the durability of Veracyte’s evidence-based competitive moat. Read the full article on Seeking AlphaAnalyse-artikel • Aug 05
Results: Veracyte, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Veracyte, Inc. ( NASDAQ:VCYT ) defied analyst predictions to release its quarterly results, which were ahead of market...
Narratiefupdate • Jul 30
VCYT: Execution Risks Around Genomic Testing Adoption Will Restrain Future Stock Repricing
Analysts have raised Veracyte's fair value estimate from $37.00 to $45.00, citing higher price targets that reflect confidence in the company's genomic testing franchises and pipeline assets. Analyst Commentary Recent Street research on Veracyte shows a split view.
Narratiefupdate • Jul 16
VCYT: Cash Generation And Pipeline Execution Will Shape Post 2026 Setup
The Analyst Price Target for Veracyte has been raised from $49.10 to $56.55. Analysts point to its cash generative profile, established Afirma and Decipher franchises, and an underappreciated pipeline as key supports for their updated assumptions.
Narratiefupdate • Jul 02
VCYT: Raised Guidance And New Cancer Tests Will Drive Medium Term Story
Veracyte's updated analyst price target has shifted higher from $53.00 to about $67.60, as analysts factor in revised assumptions around profitability, reimbursement stability in its Afirma and Decipher testing assets, and potential contribution from newer platforms such as molecular residual disease and Prosigna. Analyst Commentary Recent research on Veracyte points to a generally constructive tone, with several bullish analysts updating their models and price targets in light of company discussions and revised assumptions around its testing portfolio.Analyse-artikel • Jun 19
Veracyte (VCYT) Stock Could Be 4.5% Overvalued After Its Recent Run
Veracyte (VCYT) has drawn attention after recent share price gains over the past month and the past 3 months, prompting a closer look at how its diagnostics business and current valuation might align with investor expectations. See our latest analysis for Veracyte. At a share price of $51.29, Veracyte has seen short term momentum build, with a 30 day share price return of 23.59% feeding into a 1 year total shareholder return of 91.24% and a 3 year total shareholder return of 98.34%. If...Narratiefupdate • Jun 18
VCYT: MRD And Prosigna Execution Risks Will Restrain Future Stock Repricing
Veracyte’s analyst price target has increased by $5 to $55, with analysts highlighting the company’s Afirma and Decipher testing assets, along with potential contributions from molecular residual disease and Prosigna, as key supports for this updated view. Analyst Commentary Recent research on Veracyte highlights a mix of optimism around Afirma, Decipher, and emerging opportunities such as molecular residual disease and Prosigna, alongside reminders that sentiment is not uniformly positive.Narratiefupdate • Jun 04
VCYT: Updated Models And Trial Readouts Will Shape Post 2026 Outlook
Veracyte's analyst price target has been raised from $47.00 to $49.10. Analysts generally point to the perceived resilience of its Afirma and Decipher testing assets, along with potential upside from additional testing platforms, as key factors supporting the updated view.Narratiefupdate • May 20
VCYT: Mixed Price Revisions Will Pressure Expectations For Future Cash Flow Repricing
Narrative Update Veracyte's updated analyst price target shifts to $37.23 from $38.59, as analysts factor in a slightly higher discount rate, more moderate revenue growth expectations, a higher projected profit margin, and a lower assumed future P/E multiple, informed by recent mixed target revisions and a new bullish initiation. Analyst Commentary Recent research on Veracyte reflects a split view, with some firms turning more constructive while several bearish analysts have trimmed price targets and highlighted execution and valuation risks.Analyse-artikel • May 14
Shareholders Will Be Pleased With The Quality of Veracyte's (NASDAQ:VCYT) Earnings
When companies post strong earnings, the stock generally performs well, just like Veracyte, Inc.'s ( NASDAQ:VCYT...Narratiefupdate • Apr 28
VCYT: Revised Street Views Will Highlight Medium Term Revenue Guidance Story
Analysts now see a modestly lower upside for Veracyte, trimming the consensus price target by a few dollars to around the mid $30s. Recent research reflects a balance between reduced targets from several firms and a newer bullish initiation that emphasizes the company's longer term growth potential.Narratiefupdate • Apr 14
VCYT: Bullish Coverage And Margin Reset Will Strengthen Prostate Cancer Risk Position
Analysts now see Veracyte's fair value at $53, up from $51. This revision reflects updated assumptions around growth, profitability and valuation multiples informed by recent Street research, including both fresh coverage and revised price targets.Narratiefupdate • Mar 31
VCYT: Refreshed Models And 2026 Earnings Focus Will Support Long-Term Upside
Analysts have trimmed their average price target on Veracyte by about $1.60 to $47.00, reflecting refreshed models after recent results and updated views on revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research updates have focused on resetting expectations for Veracyte, with price targets adjusted downward and models refreshed after Q4 results.Narratiefupdate • Mar 17
VCYT: NCCN Risk Stratification Focus Will Support Future Cash Flow Repricing
Analysts have lowered their price target on Veracyte from $43.00 to about $38.59, citing updated assumptions for revenue growth, profit margins and future P/E following recent model revisions. This includes a reduced $37 target from one large Wall Street firm after Q4 results.Narratiefupdate • Mar 02
VCYT: 2026 Revenue Outlook And Higher Future P/E Will Lift Long-Term Upside
Analysts now set their Veracyte price target at $48.60, compared with $47.50 previously. This reflects updated views on revenue growth, profit margin assumptions and a higher future P/E multiple.Narratiefupdate • Feb 16
VCYT: Guideline Support And Margin Reset Will Strengthen Prostate Cancer Risk Role
Analysts have kept their $51.00 price target for Veracyte unchanged, citing updated assumptions that reflect slightly lower discount rates, modestly higher revenue growth expectations, a reduced profit margin outlook, and a higher future P/E multiple. What's in the News Veracyte issued earnings guidance for the fourth quarter of 2025, with expected total revenue between US$138 million and US$140 million, described as 16% to 18% growth for the period.Narratiefupdate • Feb 02
VCYT: NCCN Risk Stratification Focus Will Support Future Genomic Test Adoption
Narrative Update on Veracyte Analysts have kept their Veracyte fair value target steady at $43.00, citing updated NCCN prostate cancer guidelines that highlight Decipher’s role in risk stratification and support slightly adjusted assumptions for revenue growth, profit margins, and future P/E. Analyst Commentary Recent commentary points to the updated NCCN prostate cancer guidelines as a supportive data point for Veracyte’s Decipher test.Narratiefupdate • Jan 19
VCYT: NCCN Guideline Support Will Strengthen Prostate Cancer Risk Stratification Role
Analysts have lifted their price target on Veracyte from US$45.00 to US$51.00, citing updated NCCN guidelines that they view as incrementally favorable for the company’s Decipher prostate cancer test and its differentiation based on clinical evidence. Analyst Commentary Bullish analysts are framing the latest NCCN prostate cancer guideline update as a meaningful support for Veracyte’s Decipher test, especially around how it is positioned within risk stratification.Narratiefupdate • Jan 05
VCYT: NCCN Guideline Support Will Shape Future Decipher Adoption And Competitive Risks
Analysts have lifted their price target on Veracyte from $28.40 to $43.00, citing updated NCCN prostate cancer guidelines that highlight the Decipher test in key risk stratification tables as support for a higher fair value assumption. Analyst Commentary Analysts point to the updated NCCN V3.2026 prostate cancer guidelines as a supportive data point for Veracyte, highlighting that Decipher is explicitly listed in the principles of risk stratification tables across several key prostate cancer settings.Narratiefupdate • Dec 15
VCYT: Updated NCCN Guidelines Will Support Gradual Risk Stratification Adoption
Analysts have modestly raised their price target on Veracyte to approximately $47.50 from about $46.30, citing slightly stronger long term growth and profitability expectations, as well as the incremental boost from updated NCCN guidelines that further differentiate the company’s Decipher prostate cancer test. Analyst Commentary Street research characterizes the NCCN guideline update as a net positive for Veracyte, with the Decipher prostate cancer test receiving prominent placement in risk stratification tables across multiple disease stages.Narratiefupdate • Nov 29
VCYT: New NCCN Guidelines Will Support Continued Market Differentiation
Analysts have raised their price target for Veracyte from $45.30 to $46.30, citing ongoing positive inclusion of the company’s Decipher test in updated clinical guidelines as a contributing factor. Analyst Commentary Analysts have examined the recent updates to the clinical guidelines and their implications for Veracyte’s Decipher test, highlighting both opportunities and potential challenges facing the company.Analyse-artikel • Nov 22
Veracyte, Inc. (NASDAQ:VCYT) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Veracyte, Inc. ( NASDAQ:VCYT ) shares have been powering on, with a gain of 27% in the...Narratiefupdate • Nov 15
VCYT: Expanded Prostate Cancer Guidelines Will Drive Demand Ahead
Veracyte's analyst price target has been raised from $41.10 to $45.30. Analysts cite stronger guidelines support, as well as improved revenue and profit growth expectations, as key drivers.Narratiefupdate • Nov 01
VCYT: Continued Pipeline Success Will Drive Broader Health Market Expansion
Narrative Update: Veracyte Analyst Price Target Revision Analysts have slightly reduced their price target for Veracyte, lowering it by $1 to $28. They cite solid recent performance but note that larger upside may be realized further into the future.Narratiefupdate • Oct 18
Advanced Genomic And Cancer Diagnostics Will Expand Global Health Markets
Analysts have modestly raised Veracyte’s fair value estimate to $41.22 from $39.75. They cite continued product momentum and optimistic guidance, despite lingering longer-term uncertainties.Analyse-artikel • Aug 30
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders would be excited to see that the share price has had a great month, posting...Analyse-artikel • Jun 15
Veracyte, Inc.'s (NASDAQ:VCYT) Shares Lagging The Industry But So Is The Business
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Veracyte, Inc. ( NASDAQ:VCYT ) is a stock worth...Analyse-artikel • May 10
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next
As you might know, Veracyte, Inc. ( NASDAQ:VCYT ) just kicked off its latest quarterly results with some very strong...Nieuw narratief • May 07
Decipher, Afirma And MRD Tests Will Broaden Future Markets
Veracyte’s Decipher test expansion and updated NCCN guidelines could drive significant revenue growth and market share in the prostate cancer segment.Analyse-artikel • Mar 08
Shareholders Can Be Confident That Veracyte's (NASDAQ:VCYT) Earnings Are High Quality
Even though Veracyte, Inc. ( NASDAQ:VCYT ) posted strong earnings, investors appeared to be underwhelmed. We have done...Analyse-artikel • Mar 04
Veracyte, Inc. (NASDAQ:VCYT) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders that were waiting for something to happen have been dealt a blow with a 26...Analyse-artikel • Jan 09
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 50% Above Its Share Price
Key Insights Veracyte's estimated fair value is US$65.48 based on 2 Stage Free Cash Flow to Equity Veracyte is...Seeking Alpha • Dec 11
Veracyte: Getting Frothy
Summary Veracyte has seen its stock more than double since early August, driven by strong Q3 results and increased revenue guidance for FY2024. This medical diagnostic firm focused on oncology is executing well, but the stock looks a bit 'frothy' based on some valuation metrics. The analyst community is also somewhat mixed based on the stock's valuation, and there was some notable insider selling following Q3 results. Can the rally continue in Veracyte? An analysis follows in the paragraphs below. Read the full article on Seeking AlphaAnalyse-artikel • Dec 01
Veracyte, Inc. (NASDAQ:VCYT) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Veracyte, Inc. ( NASDAQ:VCYT ) shares have continued their recent momentum with a 25% gain in the last month alone. The...Analyse-artikel • Aug 18
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking After Shares Rocket 42%
Veracyte, Inc. ( NASDAQ:VCYT ) shareholders have had their patience rewarded with a 42% share price jump in the last...Analyse-artikel • Aug 09
Veracyte, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Shareholders will be ecstatic, with their stake up 39% over the past week following Veracyte, Inc. 's ( NASDAQ:VCYT...Analyse-artikel • Jul 02
Veracyte, Inc.'s (NASDAQ:VCYT) Intrinsic Value Is Potentially 76% Above Its Share Price
Key Insights The projected fair value for Veracyte is US$37.52 based on 2 Stage Free Cash Flow to Equity Veracyte's...Analyse-artikel • Jun 06
Veracyte, Inc.'s (NASDAQ:VCYT) Price Is Right But Growth Is Lacking
Veracyte, Inc.'s ( NASDAQ:VCYT ) price-to-sales (or "P/S") ratio of 4.4x might make it look like a strong buy right now...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$114m |
| Mar 31 2026 | n/a | n/a | US$88m |
| Dec 31 2025 | US$7m | US$700k | US$66m |
| Sep 30 2025 | n/a | n/a | US$30m |
| Jun 30 2025 | n/a | n/a | US$26m |
| Mar 31 2025 | n/a | n/a | US$33m |
| Dec 31 2024 | US$7m | US$675k | US$24m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$54m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$7m | US$650k | -US$74m |
| Sep 30 2023 | n/a | n/a | -US$50m |
| Jun 30 2023 | n/a | n/a | -US$29m |
| Mar 31 2023 | n/a | n/a | -US$30m |
| Dec 31 2022 | US$5m | US$625k | -US$37m |
| Sep 30 2022 | n/a | n/a | -US$43m |
| Jun 30 2022 | n/a | n/a | -US$49m |
| Mar 31 2022 | n/a | n/a | -US$48m |
| Dec 31 2021 | US$6m | US$350k | -US$76m |
Compensatie versus markt: De totale vergoeding ($USD 7.42M ) Marc } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.99M ).
Compensatie versus inkomsten: De vergoeding van Marc is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Marc Stapley (56 yo)
5.3yrs
Tenure
US$7,421,877
Compensatie
Mr. Marc A. Stapley serves as Chief Executive Officer at Veracyte, Inc. since June 1, 2021 and serves as its Director since June 08, 2021. He served as the Chief Executive Officer of Helix OpCo, LLC from A...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$7.42m | 0.20% $ 6.7m | |
| Executive VP & CFO | 5.2yrs | US$2.88m | 0.045% $ 1.5m | |
| Chief Scientific & Medical Officer | 2.9yrs | US$2.50m | 0.033% $ 1.1m | |
| Executive VP | 4.6yrs | US$2.79m | 0.0019% $ 62.6k | |
| Global Chief Commercial Officer | 4yrs | US$3.20m | 0.015% $ 507.8k | |
| Senior Vice President of Global Operations | 1.8yrs | geen gegevens | geen gegevens | |
| VP & Chief Accounting Officer | 4.6yrs | geen gegevens | 0.014% $ 470.4k | |
| Chief Development & Technology Officer | less than a year | geen gegevens | geen gegevens | |
| Senior VP & Chief Information Officer | 4.7yrs | geen gegevens | geen gegevens | |
| Director of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Corporate Marketing | 2.7yrs | geen gegevens | geen gegevens | |
| Chief Human Resources Officer | less than a year | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van VCYT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$7.42m | 0.20% $ 6.7m | |
| Independent Director | 13.8yrs | US$324.99k | 0.012% $ 404.5k | |
| Independent Director | 18.6yrs | US$324.99k | 0.037% $ 1.2m | |
| Independent Chair | 11.7yrs | US$359.99k | 0.065% $ 2.2m | |
| Independent Director | 6.1yrs | US$327.49k | 0.034% $ 1.1m | |
| Independent Director | 2yrs | US$307.49k | 0.018% $ 610.5k | |
| Member of Scientific & Technology Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Member of Scientific & Technology Advisory Board | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 5.5yrs | US$309.99k | 0.047% $ 1.5m | |
| Director and Member of Scientific & Technology Advisory Board | 2yrs | US$304.99k | 0.018% $ 610.5k | |
| Director and Member of Scientific & Technology Advisory Board | 4.1yrs | US$304.99k | 0.064% $ 2.1m | |
| Member of Scientific & Technology Advisory Board | less than a year | geen gegevens | geen gegevens |
4.7yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van VCYT wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/15 06:41 |
| Aandelenkoers aan het einde van de dag | 2026/09/14 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Veracyte, Inc. wordt gevolgd door 26 analisten. 13 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Paul Knight | Brean Capital Historical (Janney Montgomery) |
| Sung Ji Nam | BTIG |
| Kyle Mikson | Canaccord Genuity |